期刊文献+

环状RNA在结直肠癌中的作用

Role of circular RNA in colorectal cancer
原文传递
导出
摘要 环状RNA作为一种新型RNA,广泛存在于真核细胞中,是具有稳定闭合环结构的RNA分子。环状RNA因其表达特异性、稳定性成为肿瘤研究领域的热点。环状RNA参与了结直肠癌细胞增殖、凋亡、转移等病理过程,与结直肠癌的发生发展、治疗、预后预测及耐药性密切相关。本文介绍了环状RNA的生物特性、生物学功能及其在结直肠癌领域的最新研究进展,旨在初步明确结直肠癌的发病机制,发现新的诊断、预后生物标志物及治疗靶点,为改善耐药性及发展精确医疗提供新的思路。 Circular RNA(circRNA),a new type of RNA,is widely found in eukaryotic cells and is an RNA molecule with a stable closed-loop structure.CircRNA has become the focus of tumor research because of its specific expression and stability.At present,a large number of studies have shown that circRNA is involved in the pathological processes such as proliferation,apoptosis and metastasis of colorectal cancer cells,and is closely related to the occurrence and development,treatment,prognosis prediction and drug resistance of colorectal cancer.This paper reviewed the biological properties and biological functions of circRNA and its latest research progress in the field of colorectal cancer,aiming at providing preliminary clarification of the pathogenesis of colorectal cancer,discovery of new diagnostic and prognostic biomarkers and therapeutic targets,and providing new ideas for improving drug resistance and developing precision medicine.
作者 苗吉 吕紫嫣 张新军 MIAO Ji;LYU Ziyan;ZHANG Xinjun(The Affiliated Hospital of Medical School,Ningbo University,Ningbo 315000,China;Institute of Digestive Diseases,Ningbo University,Ningbo 315000,China)
出处 《生命的化学》 CAS 2021年第11期2361-2368,共8页 Chemistry of Life
基金 宁波市自然科学基金项目(2016A610121)。
关键词 环状RNA 结直肠癌 分子机制 生物标志物 治疗靶点 circular RNA colorectal cancer molecular mechanism biomarker therapeutic target
  • 相关文献

参考文献2

二级参考文献24

  • 1Van Cutsem E,Peeters M,Siena S,et al.Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology . 2007
  • 2Elena De Mattia,Giuseppe Toffoli,Jerry Polesel,Mario D’Andrea,Giuseppe Corona,Vittorina Zagonel,Angela Buonadonna,Eva Dreussi,Erika Cecchin.Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment[J].Pharmacogenetics and Genomics.2013(10)
  • 3KimieSai,YoshiroSaito,NaokoTatewaki,MasakiyoHosokawa,NahokoKaniwa,TomokoNishimaki‐Mogami,MikihikoNaito,Jun‐ichiSawada,KuniakiShirao,TetsuyaHamaguchi,NoboruYamamoto,HideoKunitoh,TomohideTamura,YasuhideYamada,YuichiroOhe,TeruhikoYoshida,HironobuMinami,AtsushiOhtsu,YasuhiroMatsumura,NagahiroSaijo,HaruhiroOkuda.Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients[J]. British Journal of Clinical Pharmacology . 2010 (2)
  • 4Leonard B. Saltz,Stephen Clarke,Eduardo Díaz-Rubio,Werner Scheithauer,Arie Figer,Ralph Wong,Sheryl Koski,Mikhail Lichinitser,Tsai-Shen Yang,Fern,o Rivera,Felix Couture,Florin Sirzén,Jim Cassi.Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Japanese Journal of Clinical Oncology . 2008
  • 5Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian Lerchenmüller,Christoph Kahl,Gernot Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,J?rg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert H?ffkes,Markus Moehler,Reinhard U Lindig,Dominik P Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncology . 2014 (10)
  • 6Jie Li,Yu Wan,Shufang Na,Xiaochan Liu,Guicheng Dong,Zheqiong Yang,Jing Yang,Jiang Yue.Sex-dependent regulation of hepatic CYP3A by growth hormone: Roles of HNF6, C/EBPα, and RXRα[J]. Biochemical Pharmacology . 2014
  • 7Ken-ichi Fujita,Tomoko Sugiura,Hidenori Okumura,Saki Umeda,Noritaka Nakamichi,Yusuke Watanabe,Hiromichi Suzuki,Yu Sunakawa,Ken Shimada,Kaori Kawara,Yasutsuna Sasaki,Yukio Kato.Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans[J]. Pharmaceutical Research . 2014 (1)
  • 8Y Claire Wang,Klim McPherson,Tim Marsh,Steven L Gortmaker,Martin Brown.Health and economic burden of the projected obesity trends in the USA and the UK[J]. The Lancet . 2011 (9793)
  • 9Michael H. Court.Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system[J]. Drug Metabolism Reviews . 2010 (1)
  • 10Hiroshi Takane,Katsuyuki Kawamoto,Tomohiro Sasaki,Kuniaki Moriki,Kazuyo Moriki,Hiroya Kitano,Shun Higuchi,Kenji Otsubo,Ichiro Ieiri.Life-threatening toxicities in a patient with UGT1A1 * 6 /* 28 and SLCO1B1 * 15 /* 15 genotypes after irinotecan-based chemotherapy[J]. Cancer Chemotherapy and Pharmacology . 2009 (6)

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部